Originally thought to arise from synovial cells, this tumour probably arises from pluripotential mesenchymal cells capable of partial or aberrant epithelial differentaition24.
This tumour accounts for approximately 10% of all soft tissue sarcomas7 and commonly arises in the para-articular deep soft tissues of the extremities of young adults. It has also been identified in the head and neck area15,18,22,23 including the third ventricle25, thorax (mediastinum, pleura, heart, lung5, heart, chest wall, pharynx, larynx), abdominal wall17, retroperitoneum27,28, stomach, mesentry26, kidney16,20, prostate19,29, vagina30, vulva21 and peritoneal cavity.
Synovial sarcomas show a specific chromosomal translocation, t(X:18)(p11.2;q11.2), which results in fusion of the SYT gene on the long arm of chromosome 18 with the SSX1, SSX2 or SSX4 gene on the short arm of the X chromosome. The transcript of the fusion gene can be demonstrated by reverse transcriptase-polymerase chain reaction in more than 90% of cases5,6 and may be identified from paraffin-embedded tissue by in situ hybridisation.
Variants
biphasic
Rarely, synovial sarcoma may show extensive calcification and ossification2 or cartilage formation. The existence of a pure epithelial variant is controversial, but may be diagnosed on a deep seated soft tissue tumour in a patient who fails to declare an epithelial primary after several years4.
Immunohistochemistry
up to 90%, 1/126 |
|
positive |
|
low MW cytokeratins |
60-70% |
93% |
|
35/3531, 18/2032, 91/9433 |
|
30%3 |
|
rarely |
|
48% |
|
some |
|
positive |
|
negative |
|
negative |
|
negative |
|
14/2210 |
|
9/3710 |
|
73/8110 |
|
88/8810 |
|
4/1810 |
|
15/638 |
|
39/4410 |
|
53/533 |
|
0/61, 12/4510 |
|
2/25, 1/126 |
|
1/126 |
|
0/25 |
|
0/25 |
|
0/25 |
|
A study of monophasic fibrous and poorly differentiated synovial sarcomas, with the diagnosis established by the presence of the translocations t(X:18)(p11.2;q11.2) has shown that reactivity for EMA, AE1/AE3 and E-cadherin, combined with negativity for CD34 is the most useful combination of markers for these problematic types of synovial sarcoma9.
The proliferative indices and expression of the pro-apoptotic factor bax are higher in the solid/glandular component than in the spindle cell component11. The latter shows a greater expression of the anti-apoptotic factor bcl-211. The SYT-SSX1 is associated with biphasic morphology13 and a higher proliferative index12.
|
solid-glandular component |
spindle cell component |
|||||
<10% |
10-30% |
>30% |
<10% |
10-30% |
>30% |
||
2/1011 |
8/1011 |
0/1011 |
10/1011 |
0/1011 |
0/1011 |
||
6/1011 |
4/1011 |
0/1011 |
2/1011 |
3/1011 |
5/1011 |
||
0/1011 |
1/1011 |
9/1011 |
10/1011 |
0/1011 |
0/1011 |
||
9/1011 |
0/1011 |
1/1011 |
2/1011 |
4/1011 |
4/1011 |
||
bax |
2/811 |
5/811 |
1/811 |
8/811 |
0/811 |
0/811 |
|
Differential diagnosis: see the immunohistochemistry of the differential diagnosis of spindle cell stromal tumours of the pleura. The t(X:18)(p11.2;q11.2) seems to have both specificity and sensitivity for synovial sarcoma and is extremely useful in cases of doubt
malignant peripheral
nerve sheath tumour: almost always negative for TLE1.
fibrosarcoma
Ewing's sarcoma/PNET
rhabdomyosarcoma
dermatofibrosarcoma protuberans with fibrosarcomatous transformation
solitary fibrous tumour
Reference9 |
cytokeratin |
|
||||
some, focally |
some focally |
50-70% |
some focally |
some focally |
||
cellular Schwannoma |
|
diffusely strongly |
|
|
||
|
|
diffusely strongly |
|
|
||
|
|
|
positive |
positive |
||
|
|
|
some |
some |
||
|
|
|
some |
some |
||
|
|
|
some |
some |
||
positive |
|
|
|
|
||
Ewing's sarcoma/PNET |
positive |
|
|
some |
some |
|
some |
|
|
|
|
||
some |
|
|
|
|
||
Prognosis
The five and ten year survival rates in one study were 68% and 41% respectively. Variables associated with an adverse outcome included tumour size >6.7 cm, poorly differentiated subtype, high nuclear atypia, mitotic count > 27/10 high-power fields, absence of stromal calcification, nuclear expression of b-catenin and Ki-67 (MIB-1) index > 27%7. A high proliferation rate and poor prognosis are associated with the SYT-SSX1 translocation14.
References
3 Diagnostic histopathology of tumors. Edited by CDM Fletcher. 2nd edition. Churchill Livingstone. Page 1525.
8 Diagnostic Immunohistochemistry edited by Professor D. J. Dabbs, page 60.
10 Chu, P. G. and L. M. Weiss (2002). "Keratin expression in human tissues and neoplasms." Histopathology 40(5): 403-39. (Summary data from multiple papers)
17 Fetsch JF,Meis JM. Synovial sarcoma of the abdominal wall. Cancer 1993; 72:469-77
29 Pan CC,Chang YH. Primary synovial sarcoma of the prostate. Histopathology 2006; 48:321-3
31 Jagdis A, Rubin BP, Tubbs RR, Pacheco M, Nielsen TO. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. Am J Surg Pathol. 2009 Dec;33(12):1743-51. Study using standard sections
32 Kosemehmetoglu K, Vrana JA, Folpe AL. TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms. Mod Pathol. 2009 Jul;22(7):872-8. Study using standard sections
33 Terry J, Saito T, Subramanian S, et al. TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol 2007; 31:240-6 Images. Study using tissue microarray
This page last revised 4.3.2010.
©SMUHT/PW Bishop